Abao, Chrismalice C.

HRN: 00-74-16  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/02/2024
CO-AMOXICLAV 625MG (TAB)
04/02/2024
04/09/2024
PO
625mg
BID
S/p Nsvd With Rmle
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: